NS: 25332330
Mobile: 90094424
2:00 – 6:00 pm (weekdays)
Sat. 10:30 AM - 1:30 PM.

News & Articles


Results of NIH-sponsored ACTIV-3 trial published

Experimental monoclonal antibody not efficacious in Phase 3 trial. Read More


NIH ACTIV Trial of blood thinners pauses enrollment of critically ill COVID-19 patients

Anticoagulation drugs did not reduce the need for organ support. Read More


Pregnant women in third trimester unlikely to pass SARS-CoV-2 infection to newborns

NIH-funded findings also suggest less-than-expected transfer of maternal SARS-CoV-2 antibodies through placenta. Read More


NIH neuroscientists isolate promising mini antibodies against COVID-19 from a llama

Preliminary results suggest anti-COVID19 nanobodies may be effective at preventing and diagnosing infections. Read More


NIH funds eight studies to uncover risk factors for COVID-19-related inflammatory syndrome in children

Awards part of a larger effort to study pediatric COVID-19 and related conditions. Read More


Reston Ebolavirus spreads efficiently in pigs

Finding reveals potential for spread to humans. Read More


NIH holds COVID-19 vaccine kick-off event

NIH Clinical Center front-line workers, Azar, Collins, Fauci to receive doses from agency’s initial stock. Read More


NIH to support radical approaches to nationwide COVID-19 testing and surveillance

RADx-rad program will fund non-traditional and repurposed technologies to combat the current pandemic and address future viral disease outbreaks. Read More


Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine

The mRNA-1273 vaccine is the second COVID-19 vaccine in the United States to be granted an EUA. Read More


Investigational COVID-19 therapeutics to be evaluated in large clinical trials

NIH trial enrolling people hospitalized with COVID-19. Read More